Jump Financial LLC Buys 5,891 Shares of Inari Medical, Inc. (NASDAQ:NARI)

Jump Financial LLC raised its stake in Inari Medical, Inc. (NASDAQ:NARI) by 15.7% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 43,328 shares of the company’s stock after acquiring an additional 5,891 shares during the period. Jump Financial LLC’s holdings in Inari Medical were worth $2,212,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in NARI. Smartleaf Asset Management LLC increased its position in Inari Medical by 128.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 634 shares of the company’s stock valued at $33,000 after purchasing an additional 356 shares during the period. R Squared Ltd acquired a new stake in shares of Inari Medical during the fourth quarter worth $45,000. Quadrant Capital Group LLC raised its stake in Inari Medical by 12.3% during the fourth quarter. Quadrant Capital Group LLC now owns 1,301 shares of the company’s stock worth $66,000 after buying an additional 143 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Inari Medical by 66.8% in the fourth quarter. GAMMA Investing LLC now owns 1,963 shares of the company’s stock valued at $100,000 after buying an additional 786 shares during the period. Finally, KBC Group NV boosted its position in Inari Medical by 31.5% during the fourth quarter. KBC Group NV now owns 2,333 shares of the company’s stock valued at $119,000 after acquiring an additional 559 shares during the last quarter. Institutional investors and hedge funds own 90.98% of the company’s stock.

Inari Medical Stock Performance

NASDAQ:NARI opened at $79.97 on Friday. Inari Medical, Inc. has a 52 week low of $36.73 and a 52 week high of $79.99. The firm has a 50-day moving average price of $79.96 and a two-hundred day moving average price of $65.21. The firm has a market cap of $4.68 billion, a price-to-earnings ratio of -59.24 and a beta of 1.02.

Wall Street Analysts Forecast Growth

NARI has been the topic of a number of recent analyst reports. William Blair reissued a “market perform” rating on shares of Inari Medical in a research note on Tuesday, January 7th. Piper Sandler increased their price target on Inari Medical from $52.00 to $80.00 and gave the stock a “neutral” rating in a report on Tuesday, January 7th. Canaccord Genuity Group reiterated a “hold” rating and issued a $80.00 price objective (up previously from $74.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Wells Fargo & Company reissued an “equal weight” rating and set a $80.00 target price (up from $65.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Finally, Baird R W lowered shares of Inari Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 7th. Twelve investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $68.00.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.